Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

• Conditions: Ovarian Cancer

• Registration Number: NCT02711865
• Lead Sponsor: Hillel Yaffe Medical Center

Brief Summary

The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-03
• Study First Submitted: 2016-03-13
• Study First Submitted QC: 2016-03-13
• Last Update Submitted: 2016-03-13
• Study First Posted: 2016-03-17
• Last Update Posted: 2016-03-17
• Study Start: 2016-05
• Primary Completion: 2019-05
• Study Completion: 2019-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

• Patients with ovarian cancer

Exclusion Criteria

• All others

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Responsive to IGF1R therapy	One year	Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.

Secondary Outcome Measures

Name	Time	Method
Proteomic Signature of IGF1R Responsive Tumors	One year	Mass Spectrometry will be used to compare IGF1R responsive and non-responsive tumors to identify the proteins associated with sensitivity to IGF1R therapy.

Trial Locations

Locations (1)

Hillel Yaffe Medical Center; 🇮🇱 Hadera, Israel